Antibody-drug conjugate · Cytotoxic, directed at EpCAM (CD326) (EPCAM) · developed by CytomX Therapeutics
Varsetatug masetecan (CX-2051) is an antibody-drug conjugate whose anti-EpCAM antibody is masked by a peptide that is cleaved by tumor-associated proteases, so the antibody binds EpCAM-expressing tumor cells. After internalization, a camptothecin derivative is released that inhibits DNA topoisomerase I. It is being studied in solid tumors and colorectal cancer.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT07900165 | Phase 1/2 | Colo-rectal Cancer | Not yet recruiting | CTMX |
| NCT06265688 | Phase 1 | Solid Tumor, Adult | Recruiting | CTMX |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Colo-rectal CancerSolid Tumor, Adult
See CTMX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
CTMX catalysts and pipeline →